Related Experiment Video

Updated: May 12, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging

Roger L Albin1, James F Burke, Robert A Koeppe

  • 1Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109-2200, USA. ralbin@umich.edu

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|April 11, 2013
PubMed
Abstract

Insights

Positron emission tomography (PET) imaging of brain amyloid and dopamine pathways can predict dementia progression in mild cognitive impairment (MCI). This molecular imaging approach aids in identifying high-risk individuals and differentiating MCI subtypes.

Area of Science:

  • Neuroscience
  • Nuclear Medicine
  • Geriatric Medicine

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Accurate classification of MCI subtypes and prediction of progression are crucial for timely intervention.
  • Current clinical classifications may not fully capture underlying neurodegenerative pathology.

Purpose of the Study:

  • To evaluate the utility of PET-based classification of neurodegenerative pathology in subjects with MCI.
  • To compare molecular imaging findings with expert clinical consensus.
  • To assess the predictive value of PET imaging for conversion to dementia.

Main Methods:

  • Cross-sectional and prospective evaluation of 27 MCI subjects.
  • Clinical classification of MCI at baseline and dementia at follow-up.
  • PET imaging using (11)C-dihydotetrabenazine for dopamine terminal integrity and (11)C-Pittsburgh compound B ((11)C-PiB) for cerebral amyloid burden.

Main Results:

  • 18 out of 27 subjects converted to dementia within a mean follow-up of 3 years.
  • PET evidence of amyloid deposition or nigrostriatal denervation strongly predicted dementia conversion.
  • Moderate concordance was observed between clinical and PET-based dementia classifications.

Conclusions:

  • Combined PET imaging of amyloid burden and dopamine integrity may identify MCI subjects at high risk for dementia.
  • Molecular imaging can help define neurochemically distinct MCI subtypes.
  • PET offers a valuable tool for understanding and classifying neurodegenerative processes in MCI.
Keywords:
Alzheimer diseaseLewy body dementiadementiafrontotemporal dementia

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...